ReviewCancer management and research2026
The Interaction of PI3K/AKT/mTOR Pathway with the Tumor Microenvironment: A Dual Engine Driving Breast Cancer Progression and Reshaping Treatment Strategies.
Review in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PI3K/AKT/mTOR signaling pathway, as a core regulatory network for cell growth, proliferation and metabolism, frequently undergoes abnormal activation in breast cancer, becoming a key driver of tumor occurrence and development. In recent years, research perspectives have shifted from solely focusing on intrinsic signals within tumor cells to the complex interactions between these cells and the tumor microenvironment (TME). This review systematically explores how the PI3K/AKT/mTOR pathway shapes an immunosuppressive, pro-angiogenic, and pro-metastatic microenvironment through interactions with immune cells, fibroblasts, vascular endothelial cells, and the extracellular matrix in the TME, thereby promoting the malignant progression, drug resistance, and recurrence of breast cancer. Additionally, it analyzes novel therapeutic strategies targeting this pathway and its interactions with the microenvironment, including combination immunotherapy, anti-angiogenic therapy, and metabolic modulation therapy, providing new ideas and potential directions to overcome the current limitations in breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.